Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphera\u2019s MesoPher Cell Therapy Demonstrates Favourable Safety and Promising Survival in a Phase II Clinical Trial in Resected Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II","country":"NETHERLANDS","productType":"Vaccine","productStatus":"New Molecular Entity","date":"May 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II"},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Last patient completed follow-up period in Phase II\/III study of Amphera\u2019s MesoPher cell therapy in mesothelioma","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphera Announces Clinical Updates of MesoPher Cell Therapy","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase II\/ Phase III","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"December 2022","url1":"","url2":"","graph1":"Oncology","graph2":"Phase II\/ Phase III"},{"orgOrder":0,"company":"Amphera","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Amphera Announces a Positive Opinion of the European Medicines Agency on the Granting of Orphan Medicinal Product Designation for MesoPher in Pancreatic Cancer","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I\/ Phase II","country":"NETHERLANDS","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"June 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I\/ Phase II"}]

    Find Clinical Drug Pipeline Developments & Deals by Amphera

    Menu

    Amphera

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Amphera

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amphera Announces a Positive Opinion of the European Medicines Agency on the Granting of Orphan Medicinal Product Designation for MesoPher in Pancreatic Cancer

              Details:

              MesoPher (Autologous Tumor Lysate-Loaded Dendritic Cell) is comprised of autologous patient DCs loaded with “PheraLys” – Amphera’s allogeneic lysate of mesothelioma cell lines and being developed for pancreatic cancer.

              Lead Product(s): Autologous Dendritic Cells Loaded PheraLys

              Therapeutic Area: Oncology Product Name: MesoPher

              Highest Development Status: Phase I/ Phase II Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amphera

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amphera Announces Clinical Updates of MesoPher Cell Therapy

              Details:

              The DENIM trial confirmed MesoPher’s excellent safety profile and MesoPher induced a robust T-cell response. The immune response did not translate into clinical benefit, and consequently the primary endpoint of an improvement of Overall Survival (OS) was not met.

              Lead Product(s): Autologous DCs Loaded With PheraLys

              Therapeutic Area: Oncology Product Name: MesoPher

              Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 12, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amphera

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Last patient completed follow-up period in Phase II/III study of Amphera’s MesoPher cell therapy in mesothelioma

              Details:

              Patients received 3 bi-weekly injections of MesoPher, plus two further injections of MesoPher after 4 and 7 months. Patients in the control arm received best supportive care alone. The primary endpoint of the study is overall survival.

              Lead Product(s): MesoPher

              Therapeutic Area: Oncology Product Name: MesoPher

              Highest Development Status: Phase II/ Phase III Product Type: Cell and Gene therapy

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable August 01, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Amphera

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Netherlands
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Amphera’s MesoPher Cell Therapy Demonstrates Favourable Safety and Promising Survival in a Phase II Clinical Trial in Resected Pancreatic Cancer

              Details:

              The latest REACtiVe data for MesoPher showed an average Overall Survival after surgery of approximately 36 months, with 8 of 10 patients alive, which is far beyond expected survival.

              Lead Product(s): MesoPher Dendritic Cell Therapy,Undisclosed

              Therapeutic Area: Oncology Product Name: MesoPher

              Highest Development Status: Phase II Product Type: Vaccine

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable May 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY